You are here:

Rabeprazole (Pariet®)


Following a full submission.

Rabeprazole is accepted for use within NHS Scotland for on-demand symptomatic treatment of moderate to severe gastro-oesophageal reflux disease (GORD) in patients without oesophagitis.

It is the second proton-pump inhibitor (PPI) with a specific licence for on-demand therapy.

Provided that there is a clearly defined need for maintenance therapy following acute treatment of GORD and that rabeprazole is considered to be the most appropriate PPI, ondemand use of rabeprazole is an effective treatment option in patients without oesophagitis.

Drug Details

Drug Name: Rabeprazole (Pariet®)
SMC Drug ID: 118/04
Manufacturer: Janssen-Cilag Ltd
Indication: Moderate to very severe gastro-oesophageal reflux disease
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 September 2004